Adicet Bio, Inc. R&D Expense

Quick Answer

Adicet Bio, Inc. reported R&D Expense of $99.13 million for fiscal year 2025.

Adicet Bio, Inc. R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2025 $99.13M -0.2%
2024 $99.32M -6.3%
2023 $106.04M +48.8%
2022 $71.25M +45.6%
2021 $48.94M +42.5%
2020 $34.33M +44.9%
2019 $23.69M +61.0%
2018 $14.72M -12.6%
2017 $16.84M

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
September 30, 2025 $22.85M -13.0% -19.6%
June 30, 2025 $28.42M +9.7% +24.6%
March 31, 2025 $22.81M -4.5% -13.1%
September 30, 2024 $26.25M +0.3% +1.4%
June 30, 2024 $25.90M -8.7% +8.4%
March 31, 2024 $23.90M -10.7% -8.7%
September 30, 2023 $26.17M +57.9% -7.7%
June 30, 2023 $28.36M +75.3% +6.0%
  • Adicet Bio, Inc. showed a decrease of -0.2% in R&D Expense compared to the prior fiscal year.
  • Over the 2017–2025 period, Adicet Bio, Inc.’s r&d expense has grown by 488.7% (from $16.84 million to $99.13 million).
  • The most recent figure is from Adicet Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment